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ABSTRACT
Background    Although endoscopic ultrasonography 
(EUS) is a useful tool for diagnosing pancreatobiliary 
diseases, not many facilities perform this technique 
as it is difficult to master. Currently, two new EUS 
systems exist: EU-ME2/GF-UCT260, manufactured 
by Olympus, and SU-1/EG-580UT, manufactured by 
Fujiﬁ lm. Some reports have compared new EUS models 
to older versions, but the operability and image quality 
of these two latest systems have not been compared. 
Our study aimed to compare the usefulness of these two 
types of EUS. 
Methods    Forty consecutive patients were recruited 
and randomized in a two-arm clinical trial; Arm 1: EU-
ME2/GF-UCT260 was used only for observation and 
SU-1/EG-580UT for EUS-ﬁ ne needle aspiration (FNA); 
Arm 2: SU-1/EG-580UT was used only for observation 
and EU-ME2/GF-UCT260 for EUS-FNA. Using a 
crossover design, we evaluated image ﬁ ndings, ease of 
scope insertion, and visibility of the gastrointestinal (GI) 
tract. Each procedure was scored using a 5-point scale 
(Clinical Trial ID: UMIN000031373).
Results    SU-1/EG-580UT was signiﬁ cantly better in 
terms of lesion-delineating capacity: lesion border (P
< 0.001), internal echo (P < 0.001). Signiﬁ cantly easier 
scope insertion was observed with SU-1/EG-580UT 
with respect to any insertion into the piriform recess (P
= 0.018), the pylorus ring (P < 0.001), and the superior 
duodenal angle (P < 0.001). Visibility during gastroin-
testinal observation was also significantly better with 
the SU-1/EG-580UT (P < 0.001) than with the EU-ME2/
GF-UCT260.
Conclusion    SU-1/EG-580UT EUS demonstrated 
superior performance during ultrasonic endoscopic GI 
observation, operability, and ultrasonic image quality.
The result of the superior ultrasound imaging quality 
of SU-1/EG-580UT EUS will aid in the identification 
of small pancreatic malignancies with unclear borders 
and prove useful in evaluating mural nodules of IPMN 
in detail. These findings could result in an increased 
use of EUS and improve identiﬁ cation and prognosis of 
patients with pancreatobiliary diseases. 
Key words    EG-580UT; endoscopic ultrasonography; 
EU-ME2; GF-UCT260; SU-1
While survival rates for many types of malignancies are 
improving, those of pancreatobiliary malignancies, es-
pecially pancreatic and biliary tract cancer, are still very 
low; therefore, early detection of lesions is indispensable 
in improving prognosis.1
 Currently, endoscopic ultrasonography (EUS) is 
becoming a popular tool for the diagnosis and treatment 
of pancreatobiliary diseases. For pancreatic cancer, 
EUS is superior in spatial resolution and has a higher 
sensitivity than other techniques, such as abdominal ul-
trasonography (AUS), computed tomography (CT), and 
magnetic resonance imaging (MRI).2–4 Furthermore, 
for pancreatic lesions smaller than 2 cm, the detection 
rate by multi detector-row CT (MDCT) decreases, while 
EUS is reported to have a high diagnostic ability of more 
than 90% in pancreatic lesions smaller than 2 cm.5–9
However, facilities where this procedure is performed 
in Japan are limited because EUS requires specialized 
training to visualize and interpret lesions compared to 
typical endoscopy and ultrasonography. Moreover, other 
drawbacks include diffi culty of scope insertion, which 
is due to forward oblique viewing of the scope and the 
image quality of the ultrasonography, which has not 
been improved since 2008. A new EUS Processor, EU-
ME2/GF-UCT260, was developed by Olympus Medical 
System Corporation (Tokyo, Japan) in 2013, while 
Fujifi lm Medical Corp (Tokyo, Japan) developed SU-1/
EG-580UT in 2015. We would have expected that ease 
of insertion and image quality of the ultrasonography 
have improved signifi cantly, especially in the SU-1/EG-
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580UT system.
 Some reports have compared new EUS models to 
older versions,10, 11 but the operability and image quality 
of these two latest systems have not been compared. 
In the present study, we compared the EU-ME2/GF-




This study is a randomized controlled crossover trial 
conducted at a single center, Tottori University Hospital 
in Yonago, Japan. This study was approved by the insti-
tutional review board of our University Hospital (approval 
number 1609B044).
Study population
Forty consecutive patients provided informed consent to 
participate in the study and were prospectively enrolled 
from December 2016 through April 2018. Patients pre-
sented with lesions detected by AUS, CT, and MRI that 
would benefi t from imaging using EUS and EUS-FNA. 
The inclusion criteria were > 20 years old and a clinical 
presence of suspicious lesions that needed a more de-
tailed observation in the gastrointestinal (GI) tract, gall 
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Fig. 1. SU-1/EG-580UT and EU-ME2/GF-UCT260. A: SU-1, B: EU-ME2, C: EG-580UT, D: GF-UCT260.
bladder/bile duct, pancreas, or lymph nodes, as well as a 
necessary histopathological diagnosis. Exclusion criteria 
were pregnancy, inability to provide informed consent, 
and patients judged inappropriate as research subjects by 
the research physician.
EUS/EUS-FNA procedure
All procedures took place with the patients under con-
scious sedation from either midazolam or dexmedeto-
midine and were performed by one of fi ve endoscopists 
used in this study, each with more than three years’ 
experience in performing EUS and EUS-FNA. We used 
two types of EUS scopes and processors (EU-ME2/
GF-UCT260 and SU-1/EG-580UT) in all cases (Fig. 1). 
Tissue samples of the lesions were collected using EUS-
FNA with a 22-G needle (EZ-shot 3 plus, Olympus 
corp., Tokyo, Japan or ExpectTM/AcquireTM, Boston 
Scientific, Marlboro, MA, USA). After the lesion was 
identifi ed, it was punctured and approximately 20 back-
and-forth movements were performed with the FNA 
needle on the target using 20 ml of suction. Whether 
tissue sampling could be performed was determined 
visually by the endoscopist and using the Target Sample 
check illuminator (TSCI), which we developed and pre-
viously reported on its utility.12 If sample collection was 
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Fig. 2. Study flow chart. Forty patients, consecutively enrolled, 
who required further examination by EUS-FNA were randomized 
into the two-arm study (SU-1/EG-580UT group and GF-UCT260 
group).





















Fig. 3. Representative EUS imaging ~Border~. Representative images from each EUS system depicting the border of lesions. As the grade 
increases, the lesion border becomes clearer. 
EUS, endoscopic ultrasonography.
Fig. 4. Representative EUS imaging ~Internal echo~. Representative images from each EUS system depicting the internal echo of lesions. 
As the grade increases, the internal structure of the lesion becomes clearer. 
EUS, endoscopic ultrasonography.
not successful the fi rst time, an additional puncture was 
performed.
Study protocol and outcome measures
Patients were randomly divided into two groups. In one 
group, EUS was performed with EU-ME2/GF-UCT260 
on either an in- or outpatient basis, while EUS-FNA was 
performed with SU-1/EG-580UT in an inpatient setting 
only; in the other group, these procedures were reversed 
(Fig. 2). These two procedures were evaluated for sever-
al parameters. The primary aim was to determine which 
modality is superior by comparing the drawability of 
the lesion using EUS (border, internal echo, septal wall). 
The secondary aim included comparison of endoscope 
insertion (piriform recess, pylorus ring, superior duode-
nal angle) and visibility in the GI tract. Each item was 
subjectively evaluated on a 5-point scale (1: poor, 2: bad, 
3: moderate, 4: good, 5: excellent), and any adverse event 
related to this study was reported (Figs. 3 and 4). With 
regard to EUS-FNA, we did not include the procedures 
related to EUS-FNA and tissue collection results in the 
study items because this study aimed to compare the 
performance only of EUS equipment (scope and proces-
sor).
Statistical analysis and sample size 
The statistical analysis was performed using SPSS ver. 
25 (IBM, Armonk, NY). Results for normally distrib-
uted continuous variables are expressed using mean 
± standard deviation. The stratified categories in each 
clinical parameter were evaluated by a paired t-test or a 
Mann-Whitney U test (in case of less than twenty in the 
category). Paired Wilcoxon signed rank test was used 
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for variables not normally distributed and McNemar test 
was used to compare the association between categorical 
variables and outcomes. P value < 0.05 was considered 
significant. The results in this study are reported in 
accordance with the CONSORT statement. 
 A power analysis (detection power of 80%) re-
vealed that samples of 38 cases (19 in each group) were 
required to confi rm the main outcome that 20% of all 
cases scored as 3 to 4 using EU-ME2/GF-UCT260 (or 
SU-1/EG-580UT) improved to scores of 4 or 5 using 
SU-1/EG-580UT (or EU-ME2/GF-UCT260) and that 24 
cases (12 cases in each group) were necessary to confi rm 
the secondary outcome that 30% of all cases scored as 
3 or 4 with EU-ME2/GF-UCT260 (or SU-1/EG-580UT) 
concerning endoscope insertion/visibility improved 
to scores of 4 or 5 by using SU-1/EG-580UT (or EU-
ME2/GF-UCT260). To ensure we did not fall short on 
required samples, we set the maximum number of cases 
and the target number of cases to 40 in this study.
RESULTS
The median age of the subjects was 71.5 years (range: 
38–85), and the ratio of males to females was 19:21. 
Pancreatic cancer was the most common primary lesion 
observed (20 subjects, 50%), followed by pancreatic 
neuroendocrine tumor (3 subjects, 7.5%), GI stromal 
tumor (2 subjects, 5%), malignant lymphoma (2 subjects, 
5%), and other lesions (benign/malignant; 9 subjects 
(22.5%)/4 subjects (10%)). Seventy percent of the total 
observed lesions were located in the pancreas, with the 
pancreatic head/body/tail involved in 12 cases (30%), 
8 cases (20%), and 10 cases (25%), respectively. The 
remaining 10 cases (25%) involved other sites, including 
the hepatic hilar. The median lesion diameter was 23.3 
mm (range: 6–88.7) (Table 1). There was no signifi cant 
difference between the two groups with respect to ex-
amination time (P = 0.442). The SU-1/EG-580UT group 
was signifi cantly better at delineating lesion capacity for 
any lesion border (P < 0.001) and at detecting an internal 
echo (P < 0.001). Statistical analysis was not possible 
with regard to the visualization ability of the septal wall 
because only two cases of cystic lesions were included 
in this study population. However, very clear septal wall 
images were obtained with SU-1/EG-580UT compared 
to those with EU-ME2/GF-UCT260 in these two cases, 
(Fig. 5). Ease of scope insertion was signifi cantly better 
in the SU-1/EG-580UT group with respect to insertion 
into the piriform recess (P = 0.018), the pylorus ring (P
< 0.001), and the superior duodenal angle (P < 0.001). 
Visibility during GI observation was also signifi cantly 
better in the SU-1/EG-580UT group (P < 0.001) (Table 2). 




Fig. 5. Representative EUS imaging ~Septal wall~. Representative 
images from each EUS system depicting the septal wall of lesions. 
Three septal walls (A: arrows) and a septal wall (B: arrow) can 
be clearly recognized in the imaging by SU-1/EG-580UT, but in 
the imaging by EU-ME2/GF-UCT260, the septal wall cannot be 
discerned.
EUS, endoscopic ultrasonography.
Table 1. Patient demographics and lesion character-
istics
Characteristics n = 40
Age (years), median (range) 71.5 (38–85)
Male:Female, n 19:21
Final diagnosis
PDAC, n (%) 20 (50)
P-NET, n (%) 3 (7.5)
GIST, n (%) 2 (5)
ML, n (%) 2 (5)
Others, n (%) 13 (32.5)
Location of lesions
Pancreatic head/body/tail, n (%) 12 (30)/8 (20)/10 (25)
Hepatic hilar, n (%) 4 (10)
Others, n (%) 6 (15)
Diameter of lesions (mm), median (range) 23.3 (6–88.7)
GIST, gastrointestinal stromal tumor; ML, malignant lymphoma; 
PDAC, pancreatic adenocarcinoma; P-NET, pancreatic neuroen-
docrine tumor.
DISCUSSION
EUS and EUS-FNA are useful tools for the diagnosis of 
pancreatobiliary diseases with poor prognosis.13 In this 
study, SU-1/EG-580UT was superior to EU-ME2/GF-
UCT260 in all parameters examined. 
 Although ultrasound imaging device resolution 
is primarily evaluated based on lateral resolution, 
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Table 2. Comparison of parameters in each EUS scope/processor
SU-1/EG-580UT EU-ME2/GF-UCT260 P-value
Procedure duration (second), 
mean (S.D.) 1195 (± 392) 1130 (± 443) 0.442
＊
Grade 1/2/3/4/5, n (%)
Drawability of 
lesions
Border 0 (0)/1 (2.5)/7 (17.5)/21 (52.5)/11 (27.5) 1 (2.5)/5 (12.5)/23 (57.5)/7 (17.5)/4 (10) ＜ 0.001†
Internal echo 0 (0)/1 (2.5)/7 (17.5)/18 (45)/14 (35) 1 (2.5)/6 (15)/17 (42.5)/12 (30)/4 (10) ＜ 0.001†
Ease of scope 
insertion
Piriform recess 1 (2.5)/5 (12.5)/15 (37.5)/16 (40)/4 (10) 3 (7.5)/9 (22.5)/16 (40)/9 (22.5)/3 (7.5) 0.025†
Pylorus ring 3 (7.5)/1 (2.5)/4 (10)/19 (47.5)/13 (32.5) 2 (5)/8 (20)/15 (37.5)/14 (35)/1 (2.5) ＜ 0.001†
SDA 0 (0)/1 (2.6)/10 (26)/19 (50)/8 (21) 2 (5.3)/5 (13.2)/19 (50)/8 (21.1)/4 (10.5) 0.001†
Visibility in GI tract 0 (0)/0 (0)/11 (17.5)/21 (52.5)/8 (20) 1 (2.5)/13 (32.5)/20 (50)/6 (15)/0 (0) ＜ 0.001†
Complications None None −
*paired t test †paired Wilcoxon singed rank test EUS, endoscopic ultrasonography; GI, gastrointestinal; SDA, superior duodenum angle.




Field of view (°) 140 100
Direction of view (°) Forward oblique viewing 40 Forward oblique viewing 55
Distal end hard portion diameter (mm) 40 45
Distal end outer diameter (mm) 13.9 14.6
Insertion tube outer diameter (mm) 12.4 12.6
Angulation range (up/down/right/left) (°) 150/150/120/120 130/90/90/90
Channel inner diameter (mm) 3.8 3.7
Ultrasound 
Functions
Frequency (MHz) 5/7.5/10/12 5/6/7.5/10/12
Scanning range (°) 150 180
Scanning Method Electronic curved linear array Electronic curved linear array
horizontal distance accuracy, and distance resolution, 
detailed data and mechanisms of EUS equipment as it 
relates to ultrasound imaging are considered proprietary 
and are not disclosed by the manufacturers. Therefore, 
understanding the improvement of ultrasound imaging 
quality from the detailed mechanism of EUS devices is 
difficult, but the 5-year period from the release of the 
EU-ME2/GF-UCT260 until the release of the SU-1/EG-
580UT appears to be a sufficient period to improve the 
ultrasound imaging quality. 
 For scope insertion and visibility during direct ob-
servation, the visual field direction is more shallow with 
the SU-1/EG-580UT at 40° than with the EU-ME2/GF-
UCT260 at 55°, and field of view is wider with the SU-1/
EG-580UT at 140° than with the EU-ME2/GF-UCT260 
at 100°, which, we believe, enabled GI tract observation 
under the visual field near the forward-viewing endo-
scope, explaining the favorable results of SU-1/EG-
580UT (Table 3). While not considered in this study, one 
disadvantage of SU-1/EG-580UT is that the scope can 
easily become erroneously positioned in the stomach 
during examinations of the descending portion of the du-
odenum. This may be due to the fact that the hard, distal 
end of the scope is shorter on SU-1/EG-580UT than on 
EU-ME2/GF-UCT260. However, because this portion is 
short, the viewing direction becomes shallower and ease 
of insertion improves, by allowing for a better balance of 
the two portions.
 According to the results of this study, all the problems 
associated with conventional EUS, like GI tract scope 
insertion and challenging ultrasound images interpreta-
tions for a diagnosis, can be overcome by using SU-1/EG-
580UT. Moreover, by using SU-1/EG-580UT, we expect 
that EUS would become a more popular technique in the 
diagnosis of pancreatobiliary diseases. In fact, the current 
EUS proficiency level of new residents at our hospital is 
increasing at a quicker pace than prior to the introduction 
of SU-1/EG-580UT (unpublished data). This study has 
limitations worth noting. The scoring evaluations were 
subjective and evaluation criteria were not strictly defined. 
Further, this was a single-center study with a small sam-
ple size. In the future, an objective evaluation of these two 
systems in a large multicenter study would be useful in 
validating these findings.  
 SU-1/EG-580UT demonstrated superior perfor-
mance compared to EU-ME2/GF-UCT260 during 
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ultrasonic endoscopic GI observation, operability, and 
ultrasonic image quality. We believe that the result of the 
superior ultrasound imaging quality of SU-1/EG-580UT 
EUS will aid in the identification of small pancreatic 
malignancies with unclear borders and prove useful in 
evaluating mural nodules of intraductal papillary mu-
cinous neoplasm in detail. We hope these findings will 
result in an increased use of EUS and an improvement 
in the identification and prognosis of patients with pan-
creatobiliary diseases.
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